Farragut Webinar | 2021 Outlook for Value-Based Care and the Self-Insured Employer Marketplace

Mar 2021

On Thursday, March 18, 2021, Lincoln International’s Barry Freeman and Michael Siano joined Farragut Square Group’s webinar, to discuss why we are seeing so many deals among value-based care (VBC)-focused providers and the self-insured employer market. Our experts from the firm’s Healthcare Group, along with fellow presenters from Stax Inc, address:

  • What VBC means in practice
  • Trends in self-insured landscape development and employer adoption of VBC
  • Sectors most relevant to the self-insured employer market and the valuations deals are trading for
  • Categories of strategic buyers currently operating in this sector and opportunities for PE investors
  • Why the market environment is fertile for these types of companies
  • The role and influence of CMS and private payers in driving progress on VBC

Please complete the form below to access to this recording:


  • On Thursday, March 18, 2021, experts from Lincoln International's Healthcare Group joined Farragut Square Group's webinar to discuss value-based care and the self-insured employer market.

  • Sign up to receive Lincoln's perspectives


Meet Professionals with Complementary Expertise

Related Perspectives

What Price is Right? Trends and Opportunities for Private Equity in Pharma Market Access

The cost of developing new drugs is staggering. Among the top 20 global biopharmas, the average cost of developing a candidate from discovery through clinical trials to market was approximately… Read More

Investment Opportunities in Pharma: A Data-Driven Exploration of CDMO Appeal

The report discusses the current state of the contract development and manufacturing organization (CDMO) market within the pharmaceutical industry, emphasizing the increased interest from private equity (PE) investors. The pharmaceutical… Read More

Scrip Asks…What Does 2024 Hold for Biopharma?

James West, Managing Director in Lincoln’s Healthcare Group, recently discussed his expectations for the biopharma market in 2024 as part of Scrip’s series. Part One – Business Strategy and Leadership… Read More

2023 Global Results

Read More